PL347298A1 - Method of obtaining (1s,2s)-1-(4-hydroxyphenyl)-2(4-phenylpiperidin-1-yl)-1-propanol methanesulphonate trihydrate, method of obtaining novel (1s,2s)-1-(4-hydroxyphenyl)-2(-4-hydroxy-4-phenylpiperidin-1-yl)-1-d-(-)-tartrate and novel (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxyphenyl)-2(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol d-(-)-tartrate as such - Google Patents

Method of obtaining (1s,2s)-1-(4-hydroxyphenyl)-2(4-phenylpiperidin-1-yl)-1-propanol methanesulphonate trihydrate, method of obtaining novel (1s,2s)-1-(4-hydroxyphenyl)-2(-4-hydroxy-4-phenylpiperidin-1-yl)-1-d-(-)-tartrate and novel (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxyphenyl)-2(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol d-(-)-tartrate as such

Info

Publication number
PL347298A1
PL347298A1 PL01347298A PL34729801A PL347298A1 PL 347298 A1 PL347298 A1 PL 347298A1 PL 01347298 A PL01347298 A PL 01347298A PL 34729801 A PL34729801 A PL 34729801A PL 347298 A1 PL347298 A1 PL 347298A1
Authority
PL
Poland
Prior art keywords
hydroxyphenyl
phenylpiperidin
tartrate
hydroxy
novel
Prior art date
Application number
PL01347298A
Other languages
English (en)
Inventor
Joseph Philip Rainville
Terry Gene Sinay Jr
Stanley Walter Walinsky
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL347298A1 publication Critical patent/PL347298A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
PL01347298A 2000-04-28 2001-04-27 Method of obtaining (1s,2s)-1-(4-hydroxyphenyl)-2(4-phenylpiperidin-1-yl)-1-propanol methanesulphonate trihydrate, method of obtaining novel (1s,2s)-1-(4-hydroxyphenyl)-2(-4-hydroxy-4-phenylpiperidin-1-yl)-1-d-(-)-tartrate and novel (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxyphenyl)-2(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol d-(-)-tartrate as such PL347298A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20067300P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
PL347298A1 true PL347298A1 (en) 2001-11-05

Family

ID=22742684

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01347298A PL347298A1 (en) 2000-04-28 2001-04-27 Method of obtaining (1s,2s)-1-(4-hydroxyphenyl)-2(4-phenylpiperidin-1-yl)-1-propanol methanesulphonate trihydrate, method of obtaining novel (1s,2s)-1-(4-hydroxyphenyl)-2(-4-hydroxy-4-phenylpiperidin-1-yl)-1-d-(-)-tartrate and novel (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxyphenyl)-2(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol d-(-)-tartrate as such

Country Status (27)

Country Link
US (1) US6645986B2 (enExample)
EP (2) EP1477479A1 (enExample)
JP (2) JP3615496B2 (enExample)
KR (1) KR100442718B1 (enExample)
CN (2) CN1590373A (enExample)
AR (1) AR028376A1 (enExample)
AT (1) ATE277014T1 (enExample)
AU (1) AU781436B2 (enExample)
BR (1) BR0101630A (enExample)
CA (1) CA2345582C (enExample)
CZ (1) CZ20011471A3 (enExample)
DE (1) DE60105689T2 (enExample)
DK (1) DK1151995T3 (enExample)
ES (1) ES2227071T3 (enExample)
HK (1) HK1040246B (enExample)
HU (1) HUP0101723A3 (enExample)
ID (1) ID30006A (enExample)
IL (1) IL142705A0 (enExample)
IN (1) IN191027B (enExample)
PL (1) PL347298A1 (enExample)
PT (1) PT1151995E (enExample)
RU (1) RU2203888C2 (enExample)
SI (1) SI1151995T1 (enExample)
TR (1) TR200402696T4 (enExample)
TW (1) TW200505858A (enExample)
YU (1) YU27701A (enExample)
ZA (1) ZA200103320B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892854B2 (en) * 2000-06-21 2011-02-22 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US7754500B2 (en) 2003-11-21 2010-07-13 Anp Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
CA2606815C (en) 2005-05-02 2017-03-07 Anp Technologies, Inc. Polymer conjugate enhanced bioassays

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
HUP9802862A3 (en) * 1995-08-11 1999-05-28 Pfizer (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate and pharmaceutical compositions containing it for treating cns disorders

Also Published As

Publication number Publication date
DE60105689T2 (de) 2005-11-10
ZA200103320B (en) 2002-10-24
JP3615496B2 (ja) 2005-02-02
HUP0101723A3 (en) 2003-03-28
TR200402696T4 (tr) 2004-11-22
EP1151995B1 (en) 2004-09-22
KR20010098960A (ko) 2001-11-08
HK1040246A1 (en) 2002-05-31
CA2345582C (en) 2006-05-30
AR028376A1 (es) 2003-05-07
IL142705A0 (en) 2002-03-10
AU781436B2 (en) 2005-05-26
CN1321638A (zh) 2001-11-14
JP2004196823A (ja) 2004-07-15
RU2203888C2 (ru) 2003-05-10
BR0101630A (pt) 2001-12-04
TW200505858A (en) 2005-02-16
EP1477479A1 (en) 2004-11-17
JP2001354651A (ja) 2001-12-25
PT1151995E (pt) 2004-11-30
CZ20011471A3 (cs) 2002-02-13
CN1210262C (zh) 2005-07-13
CA2345582A1 (en) 2001-10-28
EP1151995A1 (en) 2001-11-07
DE60105689D1 (de) 2004-10-28
US20020016465A1 (en) 2002-02-07
ID30006A (id) 2001-11-01
HU0101723D0 (en) 2001-07-30
ATE277014T1 (de) 2004-10-15
YU27701A (sh) 2003-04-30
IN191027B (enExample) 2003-09-13
AU3889601A (en) 2001-11-01
ES2227071T3 (es) 2005-04-01
HUP0101723A2 (hu) 2002-02-28
KR100442718B1 (ko) 2004-08-02
HK1040246B (zh) 2005-10-28
CN1590373A (zh) 2005-03-09
US6645986B2 (en) 2003-11-11
SI1151995T1 (en) 2004-12-31
DK1151995T3 (da) 2004-12-13

Similar Documents

Publication Publication Date Title
ATE215072T1 (de) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4- phenylpiperidin-1-yl)-1-propanol-methansulfonat trihydrat
ZA200107073B (en) Method and device for producing brushware and brushware obtained with same.
IT1317741B1 (it) Metodo per la preparazione di 5-cianoftalide.
AU2001255448A1 (en) Alpha-2 adrenergic receptor polymorphisms
PL347298A1 (en) Method of obtaining (1s,2s)-1-(4-hydroxyphenyl)-2(4-phenylpiperidin-1-yl)-1-propanol methanesulphonate trihydrate, method of obtaining novel (1s,2s)-1-(4-hydroxyphenyl)-2(-4-hydroxy-4-phenylpiperidin-1-yl)-1-d-(-)-tartrate and novel (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxyphenyl)-2(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol d-(-)-tartrate as such
IL147978A0 (en) Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists
IT1310516B1 (it) Metodo e macchina per la fascettatura di gruppi di foglietti.
IT1319242B1 (it) Processo per la preparazione di maleato di fluvossamina.
SI1149831T1 (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor
IT1317789B1 (it) Macchina per la fabbricazione di pennelli
HU0001427D0 (en) Improved process for preparing 2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazole-1-yl)-2,3-epoxy-propane
SI0843661T1 (en) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate
GB0203202D0 (en) The flavour imbued great british chip and the process for preparing "The actionaid chip"
ITBO20020704A1 (it) Macchina, utilizzante cialde, per l'erogazione di
HUP0300192A3 (en) Method for production of 1,3-disubstituted 2-nitroguanidines
ITBO980716A0 (it) Procedimento , testina e apparecchiatura per la nastratura di un conte nitore .
ITMI932398A0 (it) Procedimento per la preparazione di 1-[3-[4-(difenilmetil]-1- piperazinil]propil]-1,3-diidro-2h-benzimidazol-2-one
TW416366U (en) Improved nailing head structure for box nailing machine
TW453216U (en) Improved structure of thread-pulling head for thread-mounting machine of racket
GB0210038D0 (en) 'Improved injection method'
GB0021147D0 (en) Chemical process
SM200100017B (it) Trave spessore per bordatrici
ITRM20020229A0 (it) Processo ed apparecchiatura per la produzione di combustibile derivato dai rifiuti.
IT1307824B1 (it) Processo per la preparazione di lidocaina.
AU2002241192A1 (en) Process for the preparation of 1-(2,6,6-trimethyl-2-cyclohexene-1-yl)-but-2-ene-1-one

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)